Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14695046 | 1.00 | MAPT (0.43) | MAPTALOX12KDM4CEPHX2CNR1 | |
| SCHEMBL2229671 | 0.92 | EPHX2 (0.46) | MAPTALOX12KDM4CEPHX2CNR1 | |
| SCHEMBL2229680 | 0.92 | EPHX2 (0.46) | MAPTALOX12KDM4CEPHX2CNR1 | |
| SCHEMBL12518171 | 0.90 | KDM4C (0.47) | MAPTALOX12KDM4CCNR1CNR2 | |
| SCHEMBL14694859 | 0.90 | KDM4C (0.47) | MAPTALOX12KDM4CCNR1CNR2 | |
| SCHEMBL14695723 | 0.89 | MAPT (0.40) | MAPTALOX12KDM4CEPHX2CNR1 | |
| SCHEMBL12517948 | 0.89 | MAPT (0.40) | MAPTALOX12KDM4CEPHX2CNR1 | |
| SCHEMBL13540506 | 0.87 | ALOX12 (0.55) | MAPTALOX12KDM4CEPHX2CNR1 | |
| SCHEMBL14713105 | 0.85 | ALDH1A1 (0.47) | MAPTKDM4CEPHX2ALDH1A1 | |
| SCHEMBL14695199 | 0.84 | KDM4C (0.44) | MAPTALOX12KDM4CEPHX2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130046013-A1 | SALICYLATE FATTY ACID DERIVATIVES | HOVLAND RAGNAR (NO) | 2013-02-21 | — | — | US | disclosed |
| US-20130046013-A1 | SALICYLATE FATTY ACID DERIVATIVES | HOVLAND RAGNAR (NO) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046013-A1 | SALICYLATE FATTY ACID DERIVATIVES | FASN, SCD, FABP2 | MAPT 4029/4885ALOX12 34/4885KDM4C 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.